These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 22383166

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics.
    Sagawa K, Lin J, Jaini R, Di L.
    Pharm Res; 2023 Aug; 40(8):1927-1938. PubMed ID: 37231296
    [Abstract] [Full Text] [Related]

  • 43. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.
    Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A.
    J Clin Pharmacol; 2013 Aug; 53(8):857-65. PubMed ID: 23720017
    [Abstract] [Full Text] [Related]

  • 44. Maximizing the Impact of Physiologically Based Oral Absorption Modeling and Simulation.
    Chung JI, Kelly RC, Wahlstrom J, Wu B, Wu T, Alvarez-Nunez F.
    J Pharm Sci; 2017 Mar; 106(3):734-737. PubMed ID: 27915208
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development.
    Peters SA, Schroeder PE, Giri N, Dolgos H.
    Drug Metab Dispos; 2012 Aug; 40(8):1495-507. PubMed ID: 22566536
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C, Nalda Molina R, González-Alvarez I, Navarro-Fontestad C, García-Arieta A, Casabó VG, Bermejo M.
    Eur J Pharm Sci; 2009 Jan 31; 36(1):137-46. PubMed ID: 19028574
    [Abstract] [Full Text] [Related]

  • 51. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method.
    Yoshida K, Maeda K, Konagaya A, Kusuhara H.
    Drug Metab Dispos; 2018 Nov 31; 46(11):1805-1816. PubMed ID: 30135241
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
    Chen Y, Ma F, Lu T, Budha N, Jin JY, Kenny JR, Wong H, Hop CE, Mao J.
    Clin Pharmacokinet; 2016 Jun 31; 55(6):735-49. PubMed ID: 26692192
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.
    Pade D, Jamei M, Rostami-Hodjegan A, Turner DB.
    Biopharm Drug Dispos; 2017 Mar 31; 38(2):94-114. PubMed ID: 28214380
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.
    Baneyx G, Fukushima Y, Parrott N.
    Future Med Chem; 2012 Apr 31; 4(5):681-93. PubMed ID: 22458685
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.